Cargando…

Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is an aggressive disease, with 30% to 40% of patients failing to be cured with available primary therapy. microRNAs (miRNAs) are RNA molecules that attenuate expression of their mRNA targets. To characterize the DLBCL miRNome, we sequenced miRNAs fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Emilia L, Trinh, Diane L, Scott, David W, Chu, Andy, Krzywinski, Martin, Zhao, Yongjun, Robertson, A Gordon, Mungall, Andrew J, Schein, Jacqueline, Boyle, Merrill, Mottok, Anja, Ennishi, Daisuke, Johnson, Nathalie A, Steidl, Christian, Connors, Joseph M, Morin, Ryan D, Gascoyne, Randy D, Marra, Marco A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308918/
https://www.ncbi.nlm.nih.gov/pubmed/25723320
http://dx.doi.org/10.1186/s13059-014-0568-y
_version_ 1782354609546723328
author Lim, Emilia L
Trinh, Diane L
Scott, David W
Chu, Andy
Krzywinski, Martin
Zhao, Yongjun
Robertson, A Gordon
Mungall, Andrew J
Schein, Jacqueline
Boyle, Merrill
Mottok, Anja
Ennishi, Daisuke
Johnson, Nathalie A
Steidl, Christian
Connors, Joseph M
Morin, Ryan D
Gascoyne, Randy D
Marra, Marco A
author_facet Lim, Emilia L
Trinh, Diane L
Scott, David W
Chu, Andy
Krzywinski, Martin
Zhao, Yongjun
Robertson, A Gordon
Mungall, Andrew J
Schein, Jacqueline
Boyle, Merrill
Mottok, Anja
Ennishi, Daisuke
Johnson, Nathalie A
Steidl, Christian
Connors, Joseph M
Morin, Ryan D
Gascoyne, Randy D
Marra, Marco A
author_sort Lim, Emilia L
collection PubMed
description BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is an aggressive disease, with 30% to 40% of patients failing to be cured with available primary therapy. microRNAs (miRNAs) are RNA molecules that attenuate expression of their mRNA targets. To characterize the DLBCL miRNome, we sequenced miRNAs from 92 DLBCL and 15 benign centroblast fresh frozen samples and from 140 DLBCL formalin-fixed, paraffin-embedded tissue samples for validation. RESULTS: We identify known and candidate novel miRNAs, 25 of which are associated with survival independently of cell-of-origin and International Prognostic Index scores, which are established indicators of outcome. Of these 25 miRNAs, six miRNAs are significantly associated with survival in our validation cohort. Abundant expression of miR-28-5p, miR-214-5p, miR-339-3p, and miR-5586-5p is associated with superior outcome, while abundant expression of miR-324-5p and NOVELM00203M is associated with inferior outcome. Comparison of DLBCL miRNA-seq expression profiles with those from other cancer types identifies miRNAs that were more abundant in B-cell contexts. Unsupervised clustering of miRNAs identifies two clusters of patients that have distinct differences in their outcomes. Our integrative miRNA and mRNA expression analyses reveal that miRNAs increased in abundance in DLBCL appear to regulate the expression of genes involved in metabolism, cell cycle, and protein modification. Additionally, these miRNAs, including one candidate novel miRNA, miR-10393-3p, appear to target chromatin modification genes that are frequent targets of somatic mutation in non-Hodgkin lymphomas. CONCLUSIONS: Our comprehensive sequence analysis of the DLBCL miRNome identifies candidate novel miRNAs and miRNAs associated with survival, reinforces results from previous mutational analyses, and reveals regulatory networks of significance for lymphomagenesis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13059-014-0568-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4308918
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43089182015-01-29 Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients Lim, Emilia L Trinh, Diane L Scott, David W Chu, Andy Krzywinski, Martin Zhao, Yongjun Robertson, A Gordon Mungall, Andrew J Schein, Jacqueline Boyle, Merrill Mottok, Anja Ennishi, Daisuke Johnson, Nathalie A Steidl, Christian Connors, Joseph M Morin, Ryan D Gascoyne, Randy D Marra, Marco A Genome Biol Research BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is an aggressive disease, with 30% to 40% of patients failing to be cured with available primary therapy. microRNAs (miRNAs) are RNA molecules that attenuate expression of their mRNA targets. To characterize the DLBCL miRNome, we sequenced miRNAs from 92 DLBCL and 15 benign centroblast fresh frozen samples and from 140 DLBCL formalin-fixed, paraffin-embedded tissue samples for validation. RESULTS: We identify known and candidate novel miRNAs, 25 of which are associated with survival independently of cell-of-origin and International Prognostic Index scores, which are established indicators of outcome. Of these 25 miRNAs, six miRNAs are significantly associated with survival in our validation cohort. Abundant expression of miR-28-5p, miR-214-5p, miR-339-3p, and miR-5586-5p is associated with superior outcome, while abundant expression of miR-324-5p and NOVELM00203M is associated with inferior outcome. Comparison of DLBCL miRNA-seq expression profiles with those from other cancer types identifies miRNAs that were more abundant in B-cell contexts. Unsupervised clustering of miRNAs identifies two clusters of patients that have distinct differences in their outcomes. Our integrative miRNA and mRNA expression analyses reveal that miRNAs increased in abundance in DLBCL appear to regulate the expression of genes involved in metabolism, cell cycle, and protein modification. Additionally, these miRNAs, including one candidate novel miRNA, miR-10393-3p, appear to target chromatin modification genes that are frequent targets of somatic mutation in non-Hodgkin lymphomas. CONCLUSIONS: Our comprehensive sequence analysis of the DLBCL miRNome identifies candidate novel miRNAs and miRNAs associated with survival, reinforces results from previous mutational analyses, and reveals regulatory networks of significance for lymphomagenesis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13059-014-0568-y) contains supplementary material, which is available to authorized users. BioMed Central 2015-01-29 2015 /pmc/articles/PMC4308918/ /pubmed/25723320 http://dx.doi.org/10.1186/s13059-014-0568-y Text en © Lim et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Lim, Emilia L
Trinh, Diane L
Scott, David W
Chu, Andy
Krzywinski, Martin
Zhao, Yongjun
Robertson, A Gordon
Mungall, Andrew J
Schein, Jacqueline
Boyle, Merrill
Mottok, Anja
Ennishi, Daisuke
Johnson, Nathalie A
Steidl, Christian
Connors, Joseph M
Morin, Ryan D
Gascoyne, Randy D
Marra, Marco A
Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients
title Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients
title_full Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients
title_fullStr Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients
title_full_unstemmed Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients
title_short Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients
title_sort comprehensive mirna sequence analysis reveals survival differences in diffuse large b-cell lymphoma patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308918/
https://www.ncbi.nlm.nih.gov/pubmed/25723320
http://dx.doi.org/10.1186/s13059-014-0568-y
work_keys_str_mv AT limemilial comprehensivemirnasequenceanalysisrevealssurvivaldifferencesindiffuselargebcelllymphomapatients
AT trinhdianel comprehensivemirnasequenceanalysisrevealssurvivaldifferencesindiffuselargebcelllymphomapatients
AT scottdavidw comprehensivemirnasequenceanalysisrevealssurvivaldifferencesindiffuselargebcelllymphomapatients
AT chuandy comprehensivemirnasequenceanalysisrevealssurvivaldifferencesindiffuselargebcelllymphomapatients
AT krzywinskimartin comprehensivemirnasequenceanalysisrevealssurvivaldifferencesindiffuselargebcelllymphomapatients
AT zhaoyongjun comprehensivemirnasequenceanalysisrevealssurvivaldifferencesindiffuselargebcelllymphomapatients
AT robertsonagordon comprehensivemirnasequenceanalysisrevealssurvivaldifferencesindiffuselargebcelllymphomapatients
AT mungallandrewj comprehensivemirnasequenceanalysisrevealssurvivaldifferencesindiffuselargebcelllymphomapatients
AT scheinjacqueline comprehensivemirnasequenceanalysisrevealssurvivaldifferencesindiffuselargebcelllymphomapatients
AT boylemerrill comprehensivemirnasequenceanalysisrevealssurvivaldifferencesindiffuselargebcelllymphomapatients
AT mottokanja comprehensivemirnasequenceanalysisrevealssurvivaldifferencesindiffuselargebcelllymphomapatients
AT ennishidaisuke comprehensivemirnasequenceanalysisrevealssurvivaldifferencesindiffuselargebcelllymphomapatients
AT johnsonnathaliea comprehensivemirnasequenceanalysisrevealssurvivaldifferencesindiffuselargebcelllymphomapatients
AT steidlchristian comprehensivemirnasequenceanalysisrevealssurvivaldifferencesindiffuselargebcelllymphomapatients
AT connorsjosephm comprehensivemirnasequenceanalysisrevealssurvivaldifferencesindiffuselargebcelllymphomapatients
AT morinryand comprehensivemirnasequenceanalysisrevealssurvivaldifferencesindiffuselargebcelllymphomapatients
AT gascoynerandyd comprehensivemirnasequenceanalysisrevealssurvivaldifferencesindiffuselargebcelllymphomapatients
AT marramarcoa comprehensivemirnasequenceanalysisrevealssurvivaldifferencesindiffuselargebcelllymphomapatients